Cargando…

Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series

OBJECTIVES: Long‐term adrenocorticotropic therapy (LT‐ACTH), which consisted of 2‐4 weeks of daily injections of adrenocorticotropic hormone (ACTH) and subsequent months of weekly injections, was tried for relapsed West syndrome (WS) or other intractable epilepsies in small case reports. Our aim was...

Descripción completa

Detalles Bibliográficos
Autores principales: Baba, Shimpei, Okanishi, Tohru, Homma, Yoichiro, Yoshida, Takeshi, Goto, Tomohide, Fukasawa, Tatsuya, Kobayashi, Satoru, Kamei, Atsushi, Fujii, Yuji, Hino‐Fukuyo, Naomi, Yamada, Keitaro, Daida, Atsuro, Kawawaki, Hisashi, Hoshino, Hideki, Sejima, Hitoshi, Ishida, Yusuke, Okazaki, Tetsuya, Inui, Takehiko, Kanai, Sotaro, Motoi, Hirotaka, Itamura, Shinji, Nishimura, Mitsuyo, Enoki, Hideo, Fujimoto, Ayataka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166796/
https://www.ncbi.nlm.nih.gov/pubmed/34095686
http://dx.doi.org/10.1002/epi4.12497
_version_ 1783701572315774976
author Baba, Shimpei
Okanishi, Tohru
Homma, Yoichiro
Yoshida, Takeshi
Goto, Tomohide
Fukasawa, Tatsuya
Kobayashi, Satoru
Kamei, Atsushi
Fujii, Yuji
Hino‐Fukuyo, Naomi
Yamada, Keitaro
Daida, Atsuro
Kawawaki, Hisashi
Hoshino, Hideki
Sejima, Hitoshi
Ishida, Yusuke
Okazaki, Tetsuya
Inui, Takehiko
Kanai, Sotaro
Motoi, Hirotaka
Itamura, Shinji
Nishimura, Mitsuyo
Enoki, Hideo
Fujimoto, Ayataka
author_facet Baba, Shimpei
Okanishi, Tohru
Homma, Yoichiro
Yoshida, Takeshi
Goto, Tomohide
Fukasawa, Tatsuya
Kobayashi, Satoru
Kamei, Atsushi
Fujii, Yuji
Hino‐Fukuyo, Naomi
Yamada, Keitaro
Daida, Atsuro
Kawawaki, Hisashi
Hoshino, Hideki
Sejima, Hitoshi
Ishida, Yusuke
Okazaki, Tetsuya
Inui, Takehiko
Kanai, Sotaro
Motoi, Hirotaka
Itamura, Shinji
Nishimura, Mitsuyo
Enoki, Hideo
Fujimoto, Ayataka
author_sort Baba, Shimpei
collection PubMed
description OBJECTIVES: Long‐term adrenocorticotropic therapy (LT‐ACTH), which consisted of 2‐4 weeks of daily injections of adrenocorticotropic hormone (ACTH) and subsequent months of weekly injections, was tried for relapsed West syndrome (WS) or other intractable epilepsies in small case reports. Our aim was to explore the efficacy of LT‐ACTH for preventing WS relapse, as well as the prevalence of its adverse events. METHODS: This is a retrospective, nationwide, multicenter case series of patients with WS who underwent LT‐ACTH. Clinical information of the patients and protocol of LT‐ACTH were collected from participating institutes in this study. We defined clinical response to ACTH as achievement of hypsarrhythmia and epileptic spasms resolution. Patients who responded to daily ACTH injections were identified and assessed whether they experienced WS relapse during/after the weekly ACTH injection period. The outcome was measured by the nonrelapse rate at 24 months after daily ACTH injections using the Kaplan‐Meier method. RESULTS: Clinical information of 16 children with WS was analyzed. The median age at LT‐ACTH initiation was 14.5 months (range: 7‐68 months). Thirteen (81%) patients had previously undergone conventional ACTH treatment. The LT‐ACTH regimens comprised a median of 16 days of daily injections (range: 11‐28 days) and 10 months of weekly injections (range: 3‐22 months). Seven patients experienced WS relapse during/after subsequent weekly ACTH period, and the nonrelapse rate at 24 months after daily injections was estimated at 60.6% (95% confidence interval: 32.3%‐80.0%). Height stagnation, hypertension, and irritability were observed; lethal adverse events were not reported. SIGNIFICANCE: Our study firstly explored the efficacy of LT‐ACTH for preventing WS relapse. LT‐ACTH might be a treatment option for patients with relapsed or intractable WS; however, we note that our study is limited by its small sample size and the lack of an appropriate control group.
format Online
Article
Text
id pubmed-8166796
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81667962021-06-05 Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series Baba, Shimpei Okanishi, Tohru Homma, Yoichiro Yoshida, Takeshi Goto, Tomohide Fukasawa, Tatsuya Kobayashi, Satoru Kamei, Atsushi Fujii, Yuji Hino‐Fukuyo, Naomi Yamada, Keitaro Daida, Atsuro Kawawaki, Hisashi Hoshino, Hideki Sejima, Hitoshi Ishida, Yusuke Okazaki, Tetsuya Inui, Takehiko Kanai, Sotaro Motoi, Hirotaka Itamura, Shinji Nishimura, Mitsuyo Enoki, Hideo Fujimoto, Ayataka Epilepsia Open Full‐length Original Research OBJECTIVES: Long‐term adrenocorticotropic therapy (LT‐ACTH), which consisted of 2‐4 weeks of daily injections of adrenocorticotropic hormone (ACTH) and subsequent months of weekly injections, was tried for relapsed West syndrome (WS) or other intractable epilepsies in small case reports. Our aim was to explore the efficacy of LT‐ACTH for preventing WS relapse, as well as the prevalence of its adverse events. METHODS: This is a retrospective, nationwide, multicenter case series of patients with WS who underwent LT‐ACTH. Clinical information of the patients and protocol of LT‐ACTH were collected from participating institutes in this study. We defined clinical response to ACTH as achievement of hypsarrhythmia and epileptic spasms resolution. Patients who responded to daily ACTH injections were identified and assessed whether they experienced WS relapse during/after the weekly ACTH injection period. The outcome was measured by the nonrelapse rate at 24 months after daily ACTH injections using the Kaplan‐Meier method. RESULTS: Clinical information of 16 children with WS was analyzed. The median age at LT‐ACTH initiation was 14.5 months (range: 7‐68 months). Thirteen (81%) patients had previously undergone conventional ACTH treatment. The LT‐ACTH regimens comprised a median of 16 days of daily injections (range: 11‐28 days) and 10 months of weekly injections (range: 3‐22 months). Seven patients experienced WS relapse during/after subsequent weekly ACTH period, and the nonrelapse rate at 24 months after daily injections was estimated at 60.6% (95% confidence interval: 32.3%‐80.0%). Height stagnation, hypertension, and irritability were observed; lethal adverse events were not reported. SIGNIFICANCE: Our study firstly explored the efficacy of LT‐ACTH for preventing WS relapse. LT‐ACTH might be a treatment option for patients with relapsed or intractable WS; however, we note that our study is limited by its small sample size and the lack of an appropriate control group. John Wiley and Sons Inc. 2021-05-28 /pmc/articles/PMC8166796/ /pubmed/34095686 http://dx.doi.org/10.1002/epi4.12497 Text en © 2021 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Full‐length Original Research
Baba, Shimpei
Okanishi, Tohru
Homma, Yoichiro
Yoshida, Takeshi
Goto, Tomohide
Fukasawa, Tatsuya
Kobayashi, Satoru
Kamei, Atsushi
Fujii, Yuji
Hino‐Fukuyo, Naomi
Yamada, Keitaro
Daida, Atsuro
Kawawaki, Hisashi
Hoshino, Hideki
Sejima, Hitoshi
Ishida, Yusuke
Okazaki, Tetsuya
Inui, Takehiko
Kanai, Sotaro
Motoi, Hirotaka
Itamura, Shinji
Nishimura, Mitsuyo
Enoki, Hideo
Fujimoto, Ayataka
Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series
title Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series
title_full Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series
title_fullStr Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series
title_full_unstemmed Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series
title_short Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series
title_sort efficacy of long‐term adrenocorticotropic hormone therapy for west syndrome: a retrospective multicenter case series
topic Full‐length Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166796/
https://www.ncbi.nlm.nih.gov/pubmed/34095686
http://dx.doi.org/10.1002/epi4.12497
work_keys_str_mv AT babashimpei efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT okanishitohru efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT hommayoichiro efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT yoshidatakeshi efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT gototomohide efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT fukasawatatsuya efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT kobayashisatoru efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT kameiatsushi efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT fujiiyuji efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT hinofukuyonaomi efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT yamadakeitaro efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT daidaatsuro efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT kawawakihisashi efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT hoshinohideki efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT sejimahitoshi efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT ishidayusuke efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT okazakitetsuya efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT inuitakehiko efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT kanaisotaro efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT motoihirotaka efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT itamurashinji efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT nishimuramitsuyo efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT enokihideo efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries
AT fujimotoayataka efficacyoflongtermadrenocorticotropichormonetherapyforwestsyndromearetrospectivemulticentercaseseries